

REFERENCES

- **Abdelmalek MF, Angulo P, Jorgensen RA, et al. (2001):** Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. *Am J Gastroenterol*; 96: 2711-7.
- **Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F and Matsuzawa Y. (2003):** Decreased plasma adiponectin concentration in patients with essential hypertension. *Am J Hypertens*; 16: 72-75.
- **Adams L, Angulo P, Jorgensen R and Lindor K. (2005):** Effect of pentoxifylline in nonalcoholic fatty liver disease is dependent on gender. *Gastroenterology*; 128(suppl 2): A-766. [Poster M1690].
- **Ahren B. (2000):** Autonomic regulation of islet hormone secretion. Implications for health and disease. *Diabetologia*; 43: 393-410.
- **Ahren B and Pacini G. (2005):** Islet adaptation to insulin resistance. *Diabetes, Obesity and Metabolism*; 7:2-8.
- **Aldred HE, Hardman AE and Taylor S. (1995):** Influence of 12 weeks of training by brisk walking on postprandial lipemia and insulinemia in sedentary middle-aged women. *Metabolism*; 44: 390-397.
- **Andersen T, Gluud C, Franzmann MB and Christoffersen P. (1991):** Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol*; 12: 224-229.
- **Angulo P, Keach JC, Batts KP and Lindor KD. (1999):** Independent predictors liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology*; 30: 1356-62.

- **Angulo p. (2002):** Nonalcoholic fatty liver disease. The New England Journal Of Medicine; 346: 1221-1231.
- **Bacon BR, Farahvash MJ, Janney CG and Neuschwander-Tetri BA. (1994):** Nonalcoholic steatohepatitis: an expanded clinical entity. Journal Of Gastroenterology; 107: 1103-9.
- **Bailey CJ and Turner RC. (1996):** Metformin. N Engl J Med; 334: 574-9.
- **Baldrige AD, Peres-Atayde AR, Graeme-Cook F, Higgins L and Lavine JE. (1995):** Idiopathic steatohepatitis in childhood: a multicenter retrospective study. J Pediatr; 127: 700-4.
- **Baranova A, Collantes R, Schlauch K, Nedvedcova Y, Fyodor P, and Marinov N. (2005):** Adiponectin gene expression in the intra-abdominal adipose tissue of patients with non-alcoholic fatty liver disease (NAFLD): Diabetic vs non-diabetics. Gastroenterology; 128(suppl 2): A-704. [Poster S1234].
- **Barham D and Trinder P. (1972):** Analyst; 97: 142.
- **Bartels H, Popper H and Dago R. (1971):** Mod. Method. Clin. Chim. Acta; 32: 81.
- **Bass NM. (2005):** Second world congress on insulin resistance syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care; 28: 1518-1523.
- **Bellentani S, Saccoccio G, Masutti F, Brutti K, Zambrotta Y and Giovani T. (2000):** Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med; 132: 112-7.
- **Berg AH, Combs TP and Scherer PE. (2002):** Adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinal Metabolism; 13: 84-89.

- **Bergman RN, Van Citters GW, Mittelman SD, Shussel HM and Gute GT. (2001):** Central role of the adipocyte in the metabolic syndrome. *J Investig Med*; 49: 119-126.
- **Berk E, Kovera A, Boozer C, Pi-Sunyer FX, Johnson J and Albu J. (2003):** Adiponectin levels and insulin sensitivity during low and high fat diets in obese, premenopausal, non-diabetic women. *Obes Res*; 11: A-34.
- **Biol J. (2002):** Adiponectin exerts a preventive effect on vascular stenosis in the injured artery. *Chem.*; Vol. 277, Issue 40, October 4: 37487-37491.
- **Blaszyk H, Ferrentino N, Forsell S, Bodolosky H, Nagi I and Kovsky T. (2005):** A pilot study of metformin as treatment for nonalcoholic steatohepatitis. *Gastroenterology*; 128(suppl 2): A-769. [Poster M1699].
- **Bloomgarden ZT. (2004):** The 1st World Congress on the insulin resistance syndrome. *Diabetes Care*; 27(2): 602-9.
- **Bloomgarden ZT. (2005):** Second world congress on insulin resistance syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. *Diabetes Care*; 28: 1518-1523.
- **Bobber T, Rochlitz H, Wegewitz U, Akpulat S, Mai K, Weikert MO, Mohlig M, Pfeiffer AF and Spranger J:** Changes of adiponectin oligomer composition by moderate weight reduction. *Diabetes*; 54(9): 2712-2719.
- **Boden G, Chen X and Iqbal N. (1998):** Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. *Diabetes*; 47: 1609-1612.
- **Boden G. (1997):** Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. *Diabetes*; 46: 3-10.

- **Bogdanova K, Poczatкова H, Uherkova L, Riegrova D, Rypka M, Feher J, Marchesini G, and Vesely J. (2006):** Non-alcoholic fatty liver disease (NAFLD)-a novel common aspect of the metabolic syndrome. Biomed pap med Fac Univ Palacky Olomouc Czech Repub.; 150(1): 101-104.
- **Bonkovsky HL, Jawaaid Q, Tortorelli K, Radovan K and Miroslav R. (1999):** Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol; 31: 421-9.
- **Brandi LS, Santoro D, Natali A, Ivanovna M, Turb J and Klosa I. (1993):** Insulin resistance of stress: sites and mechanisms. Clin Sci (Colch); 85: 525-535.
- **Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR. (1999):** Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol; 94: 2467-74.
- **Bugianesia E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Lasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R and Marchesini G. (2005):** Adiponectin in nonalcoholic fatty liver disease. The Journal of Clinical Endocrinology and Metabolism; 90(6): 3498-3504.
- **Caldwell SH, Swerdlow RH, Khan EM, Liberman J and Smith K. (1999):** Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol; 31: 430-4.
- **Calles-Escandon J, Goran MI, O'Connell M, Paul E, Shredin Y and Nivelle G. (1996):** Exercise increases fat oxidation at rest unrelated to changes in energy balance or lipolysis. Am J Physiol; 270: E1009-E1014.

- **Cao H and Hegele RA. (2000):** Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy. *Human and Molecular Genetics*; 9: 109-112.
- **Carmina E and Lobo RA. (1999):** Polycystic ovary syndrome (PCOS); arguably the most common endocrinopathy is associated with significant morbidity in women. *J Clin Endocrinol Metab*; 84: 1897-9.
- **Cavallo-Perin P, Bruno A, Boine L, Cassader M, Lenti G and Pagano G. (1988):** Insulin resistance in Grave's disease; a quantitative in vivo evaluation. *Eu J Clin Invest*; 18: 607-13.
- **Chan N, Kong A, Tong P, Leung G and Chan J. (2006):** Adiponectin: a potential therapeutic target in the management of the metabolic syndrome. *Medical Progress*; June: 271-276.
- **Chavin KD, Yang SQ, Lin HZ, Hwang LK and Lee DG. (1999):** Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Biol Chem*; 274: 5692-700.
- **Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD and Kahn SE. (2003):** Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. *Diabetologia*; 46: 459-469.
- **Cohen B, Novick D and Rubinstein M. (1996):** Modulation of insulin activities by leptin. *Science*; 274: 1185-8.
- **Combs TP, Berg AH, Obici S, Scherer PE and Rossetti L. (2001):** Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *Journal of Clinical Investigation*; 108: 1875-1881.
- **Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'rahilly S, Savage DB, Chatterjee K, Weiss S,**

- Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE and Moller DE. (2002):** Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR γ agonists: a potential mechanism of insulin sensitization. *Endocrinology*; 143: 998-1007.
- **Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A and Diehl AM. (1999):** Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. *JAMA*; 282: 1659-64.
 - **Day C. (2005):** Second world congress on insulin resistance syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. *Diabetes Care*; 28: 1518-1523.
 - **DeFronzo RA and Ferrannini E. (1991):** Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care*; 14: 173-94.
 - **Delrio G, Procopio M, Bondi M, Vallantini T, Rossi E and Fiori G. (1997):** Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. *Int J Obes Relat Metab Disord*; 21: 1111-1114.
 - **Despres, J.P. (2001):** Health consequences of visceral obesity. *Ann. Med*; 33: 534-541.
 - **Diehl AM. (2002):** Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. *Am J Physiol*; 282: 1-5
 - **Donahue RP, Prineas RJ, Donahue RD, Bond H, Haward O AND Kenny L. (1999):** Is fasting leptin associated with insulin resistance

among nondiabetic individuals? The Miami Community Health Study. *Diabetes Care* 1999; 22: 1092-1096.

- **Drucker DJ. (2002):** Biological actions and therapeutic potential of the glucagon-like peptides. *Gastroenterology*; 122: 531-544.
- **Eliasson B, Taskinen MR and Smith U. (1996):** Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. *Circulation*; 94: 878-881.
- **Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW and Cooney GJ. (2000):** Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. *American Journal of Physiology*; 279: E554-E560.
- **National Cholesterol Education Program (NCEP). (2001):** Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*; 285: 2486-2497.
- **Facchini FS, Hollenbeck CB, Jeppersen J, Dan L, Forest M and Judy B. (1992):** Insulin resistance and cigarette smoking. *Lancet*; 339: 1128-1130.
- **Fan C-Y, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. (1998):** Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase: implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. *J Biol Chem*; 273: 15639-45.
- **Fasshauer M, Klein J, Lossner U and Paschke R. (2002):** Isoproterenol is a positive regulator of the suppressor of cytokine signaling-3 gene expression in 3T3-L1 adipocytes. *J Endocrinol*; 175: 727-733.

- **Flier JS, Kahn CR and Roth J. (1979):** Receptors, antireceptor antibodies and mechanisms of insulin resistance. *N. Engl. J. Med*; 300 (8): 413-419
- **Franzese A, Vajro P, Argenziano A, Cabreati E, Basta J and Bernardo R. (1997):** Liver involvement in obese children: ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. *Dig Dis Sci*; 42: 1428-32.
- **Frati Munari AC, Benitez Pinto W, Raul Ariza Andraca C and Casarrubias M. (1998):** Lowering glycemic index of food by acarbose and Plantago psyllium mucilage. *Arch Med Res*; 29: 137-141.
- **Frayn KN. (2001):** Adipose tissue and insulin resistance syndrome. *Proceeding of the Nutrition Society*; 60: 375- 380.
- **Friedman TC, Mastorakos G, Newman TD, Henry K, Osman G and Russel N. (1996):** Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM. *Endocr J*; 43: 645-655.
- **Fuerst ML. (2004):** Blood Test for Two Markers of Non-Alcoholic Fatty Liver Disease May Replace Liver Biopsy. *Doctors Guide*, November: 225-233.
- **Garg A. (1996):** Insulin resistance in the pathogenesis of dyslipidemia. *Diabetes Care*; 19: 387-9.
- **Gavrila A, Chan JI, Yinnakouris A, Kontogianni M, Miller LC, Orlova C and Mantzoros CS. (2003):** Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. *J Clin Endocrinol Metab*; 88: 4823-4831.

- **Gavrilova O, Marcus Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, Vinson C, Eckhaus M and Reitman ML. (2000):** Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. *Journal of Clinical Investigation*; 105: 271-278.
- **Goldstein RE, Wasserman DH, McGuinness OP, Hans KL, Kalvin PT and Konnor HM. (1993):** Effects of chronic elevation in plasma cortisol on hepatic carbohydrate metabolism. *Am J Physiol*; 264: E119-E127.
- **Gregory S. Kelly and ND. (2000):** Insulin resistance. *Alternative Medicine Review*; □ Volume 5, Number 2: 109-132.
- **Haffner SM, Miettien H and Stem MP. (1997):** The homeostasis model in the San Antonio Heart Study. *Diabetes Care*; 20: 1087-92.
- **Haluz KM, Parzkov J and Haluz KM (2004):** Adiponectin and its role in the obesity induced insulin resistance and related complications. *Physiol Res*; 53: 123-129.
- **Hamann A and Matthaei S. (1996):** Regulation of energy balance by leptin. *Exp Clin Endocrinol Diabetes*; 104: 293-300.
- **Harrison S, Belfort R, Brown K, Stem B and Lary C. (2005):** A double-blind, placebo-controlled trial of pioglitazone in the treatment of non-alcoholic steatohepatitis (NASH). *Gastroenterology*; 128(suppl 2): A-681. [Abstract 1].
- **Havel PJ. (2002):** Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. *Curr Opin Lipidol*; 13: 51-59.
- **Horber FF, Kohler SA, Lippuner K and Jaeger P. (1996):** Effect of regular physical training on age associated alteration of body composition in men. *Eur J Clin Invest*; 26: 279-285.

- **Hotamisligil GS, Peraldi SP, Budavari A, Ellis R, White MF and Spiegelman BM. (1996):** IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF- α - and obesity-induced insulin resistance. *Science*; 271: 665-8.
- **Huang H, Merriman RB, Chokkalingam AP, Goldman H, Fodry B and Chang D. (2005):** Novel genetic markers associated with risk of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver diseases. *Gastroenterology*; 128(suppl 2): A-694.
- **Hughes VA, Fiatarone MA, Fielding RA, Danny KJ and Totti A. (1993):** Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. *Am J Physiol*; 264: E855-E862.
- **Hyogo H, Iwamoto K, Arihiro K, Yamamoto K, Omata D and Suchi D. (2005):** Glyceraldehyde-derived advanced glycation end products as the predictive factor for the disease progression in nonalcoholic steatohepatitis. *Gastroenterology*; 128(suppl 2): A-768. [Poster M1695].
- **Itoh Y, Kawamata Y, Harada M, Boma L, Hago T and Deng J. (2003):** Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. *Nature*; 422: 173-176.
- **Iwamoto K, Hyogo H, Ajima T, Nagwia M and Tanaka G. (2005):** Role of advanced glycation end products (AGE) and their receptors (RAGE) in the pathogenesis of nonalcoholic steatohepatitis (NASH). *Gastroenterology*; 128(suppl 2): A-695. [Abstract 471].
J Clin Invest; 106: 171-176.
- **Jayaraman AK, Clark JM, Solga SF, Jade F, Claudy N and Colin D. (2005):** Iron Stores, ALT and hepatic steatosis in overweight adults with type 2 diabetes. *Gastroenterology*; 128(suppl 2): A-768. [Poster M1696].

- **Johnson J, Flancbaum L and Albu J. (2003):** Adiponectin release in deep subcutaneous abdominal and visceral tissue depots. *Obes Res* 11: A-34.
- **Jones RL. (2003):** Insulin resistance, diet and cardiovascular disease: a review. *Food, Agriculture & Environment*; Vol.1: 26-29.
- **Joseph AE, Saverymuttu SH, al-Sam S, Cook MG and Maxwell JD. (1991):** Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol*; 43: 26-31.
- **Joy D, Thava VR and Scott BB. (2003):** Diagnosis of fatty liver disease: is biopsy necessary?. *Eur J Gastroenterol Hepatol*; 15:539-543.
- **Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T and Matsuzawa Y. (2003):** Enhanced carbon tetrachloride- induced liver fibrosis in mice lacking adiponectin. *Gastroenterology*; 125: 1796-1807.
- **Karhapaa P, Malkki M and Laakso M. (1994):** Isolated low HDL cholesterol. An insulin-resistant state. *Diabetes*; 43: 411-7.
- **Katz A, Nambi SS, Mather K, Joseph B, Ivram S and David K. (2000):** Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab*; 85: 2402-10.
- **Keilin D and Hartee EF. (1948):** *Biochem J*; 42: 230.
- **Kelley DE, Goodpaster B, Wing RR and Soimoneau JA. (1999):** Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. *Am J Physiol*; 277: E1130-E1141.
- **Kelly DE, McKolanis TM, Hegazi RA, Kuller LH and Kalhan SC. (2003):** Fatty liver in type 2 diabetes mellitus: Relation to regional

- adiposity, fatty acids, and insulin resistance. *Am J Physiol Endocrinol Metab*; 285: E906-16.
- **Kenney JJ. (2003):** Diet to prevent and reverse insulin resistance and type 2 diabetes mellitus. *Food and Health communications*; 11(26): 1-10.
 - **Khieffer TJ and Habener JF. (2000):** The adipoinsular axis: effects of leptin on pancreatic beta-cells. *Am J Physiol*; 278: E1-E14.
 - **Kim JK, Gavrilova O, Chen Y, Reitman ML and Shulman GI. (2000):** Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. *Journal of Biological Chemistry*; 275: 8456-8460.
 - **Kinoshita O, Kubo K and Kusama S. (1988):** A case of insulin resistant diabetes mellitus due to insulin receptor antibodies with Sjogren's Syndrome. *Nippon Naika Gakkai Zasshi*; 77: 1572-5.
 - **Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB and Korbonits M. (2005):** Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMPactivated protein kinase. *J Biol Chem*; 280: 25196-25201.
 - **Laakso M. (1993):** How good a marker is insulin level for insulin resistance? *Am J Epidemiol*; 137: 959-65.
 - **Lauren J, Lindor KD, Crippin JS, Bernard K, Janey L and Winselt B. (1996):** Ursodeoxycholic acid or colfibrate in the treatment of non-alcoholic induced steatohepatitis: pilot study. *Hepatology*; 23: 1464-7.
 - **Lavine JE. (2000):** Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. *J peditar*; 136: 734-7.
 - **Lehmann R, Vokac A, Niedermann K, York M and Wiseman H. (1995):** Loss of abdominal fat and improvement of the cardiovascular risk profile by regular moderate exercise training in patients with NIDDM. *Diabetologia*; 38: 1313-1319.

- **Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman HI, Langefeld CD, Carr JJ and Bowden DW. (2003):** Adiponectin as a novel determinant of bone mineral density and visceral fat. *Bone*; 33: 646-651.
- **Li Z. (2003):** Probiotics and antibodies to tumor necrosis factor alpha inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology*; 37: 343-350.
- **Lihn A, Yunk-Wook KK, Bruun J, Pedersen S and Richelsen B. (2003):** Human in vitro and in vivo effects of thiazolidinediones on adiponectin. *Obes Res*; 11: A-35.
- **Low I, Chernausek SD and Sperlin MA. (1989):** Acromegaloid patients with type A Insulin resistance; parallel defects in insulin and insulin-like growth factor-I receptors and biological responses in cultured fibroblasts. *J Clin Endocrinol Metab*; 69: 329-37.
- **Ludwig DS, Pereira MA, Kroenke CH, Hilner JE, Van Horn L, Slattery ML, Sperlin H, Daniel J and Selvan S. (1999):** Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. *JAMA*; 282: 1539-46.
- **Lutchman G, Promrat K, Kleiner DE, Fan T, Roy J and Cort M. (2005):** Durability of histological and biochemical improvement after stopping pioglitazone therapy for nonalcoholic steatohepatitis (NASH). Is long-term therapy needed? *Gastroenterology*; 128(suppl 2): A-695. [Abstract 472].
- **Luyckx FH, Desaive C, Thiry A, Vladimir B and Yan P. (1998):** Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *Int J Obes Relat Metab Disord*; 22: 222-6.

- **Maddux BA, Sbraccia P, Kumakura S, Imota G and Daket O. (1995):** Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. *Nature*; 373: 448-51.
- **Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ and Couper RTL. (2000):** Non-alcoholic steatohepatitis in children and adolescents. *Med J Aust*; 173: 476-9.
- **Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN and Karl JG. (1999):** Liver pathology and metabolic syndrome x in severe obesity. *J Clin Endocrinal Metab*; 84: 1513-7.
- **Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M and Melchionda N. (2001):** Metformin in non-alcoholic steatohepatitis. *Lancet*; 358: 893-4.
- **Marchesini G, Brizi M, Morselli-Labate AM, Angulo P, Falantiano P and Taury L. (1999):** Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med*; 107: 450-5.
- **Marshall JA, Bessesen DH and Hamman RF. (1997):** High saturated fat and low starch and fiber are associated with hyperinsulinaemia in a nondiabetic population: The San Luis Valley Diabetes Study. *Diabetologia*; 40: 430-438.
- **Martin BC, Warram JH, Krolewski AS, Bond d and Beck I. (1992):** Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. *Lancet*; 340: 925-929.
- **Matsubara M, Maruoka S, and Katayose S. (2002):** Decreased adiponectin in dyslipidemia. *J Clin Endocrinol Metab*; 87(6): 2764-2769.
- **Matsuzawa Y, Bogardus C and Tataranni PA. (2003):** Plasma adiponectin and endogenous glucose production in humans. *Diabetes Care*; 26: 3315–3319.

- **Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC and Mc-Cullough AJ. (1999):** Nonalcoholic fatty liver disease: a spectrum of clinical pathological severity. *Gastroenterology*; 116: 1413-9.
- **Meier U and Gressner AM. (2004):** Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. *Clin Chem*; 50: 1511-1525.
- **Mendler MH, Turlin B, Moirand R, Tory L, Charles J, Heiel G and Keilen L. (1999):** Insulin resistance-associated hepatic iron overload. *Gastroenterology*; 117: 1155-63.
- **Mtteoni CA, Younossi ZM, Gramlich T, Freiburg J and Helmer O. (1997):** Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology*; 116: 1413-9.
- **Nedvidcova J, Smitka K, Kopsky V and Hainer V. (2005):** Adiponectin, an Adipocyte-Derived protein. *Physiol. Res*; 54: 133-140.
- **Nilsson PM, Moller L and Solstad K. (1995):** Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. *J Intern Med*; 237: 479-486.
- **Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T and Matsuzawa Y. (2002):** Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte derived protein. *Diabetes*; 51: 2734-2741.
- **Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S and Goto M. (1988):** Prevalence of fatty liver in a general population of Okinawa, Japan. *Jpn J Med*; 27: 142-9.
- **Olatunbosun S and Dagogo-Jack S. (2004):** Insulin resistance. *Emedecine*; June: Section 1-10.

- **Osei K. (1999):** Insulin resistance and systemic hypertension. *Am J Cardiol*; 84: 33J-6J.
- **Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L and Kunos G. (2005):** Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J Clin Invest*; 115: 1298-1305.
- **Ott V, Fasshauer M, Dalski A, Meier B, Perwitz N, Klein HH, Tschop M and Klein J. (2002):** Direct peripheral effects of ghrelin include suppression of adiponectin expression. *Horm Metab Res*; 34: 640-645.
- **Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T and Walsh K. (2004):** Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. *J Biol Chem*; 279: 1304-1309.
- **Oz HS, Im H, McClain CJ, Mcmanaman G and Dany OG. (2005):** Novel action of a cysteine prodrug, 2(rs)-N-propylthiazolidine-4®-carboxylic acid (PTCA) against liver injury in a dietary NASH model. *Gastroenterology*; 128(suppl 2): A-686. [Abstract 183].
- **Pagano C, Sovado G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi AL and Vettor R. (2005):** Plasma adiponectin is decreased in nonalcoholic fatty liver disease. *Clin. Endocrinol. Metab.*; June; 90(6): 3498 -3504
- **Pagotto U, Marsicano G, Cota D, Lutz B and Pasquali R. (2005):** The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocrine Reviews*; Published November 23, as doi: 10.1210/er.2005-0009.

- **Parillo M, Rivellese AA, Ciardullo AV, Panoti R, Grazziani P and Ponty F. (1992):** A high monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients. *Metabolism*; 41: 1373-1378.
- **Patton CJ and Crouch SR. (1977):** *Anal. Chem*; 49: 464-469.
- **Pederson O, Richelson B, Bak J, Anfred J, Weeke J and Schmitz O. (1988):** Characterization of the insulin resistance of glucose utilisation in adipocytes from patients with hyperthyroidism and hypothyroidism. *Acta Endocrine(Copenh)*; 119: 228-234.
- **Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G and Trichopoulos D. (2003):** Plasma Adiponectin Concentrations in Relation to Endometrial Cancer: A Case-Control Study in Greece. *The Journal of Clinical Endocrinology & Metabolism*; Vol. 88, No. 3: 993-997.
- **Petrie A and Sabin C. (2000):** *Medical statistics at a glance (book)*.
- **Peterson J. (2003):** biology and pathophysiology of fat-derived hormone adiponectin. *Phoenix Pharmaceuticals, Inc.* June; 27: 1-32.
- **Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A and De Moura MC. (1996):** Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. *Dig Dis Sci*; 41: 172-9.
- **Pittas G, Joseph NA, and Greenberg AS (2004):** Adipocytokines and Insulin Resistance. *The Journal of Clinical Endocrinology & Metabolism*; 89(2): 447-452
- **Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z and Albrecht J. (2003):** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology*; 38: 75-85.

- **Prentki M and Corkey BE. (1996):** Are the beta-cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM?. *Diabetes*; 45: 273-283.
- **Raikkonen K, Keltikangas-Jarvinen L, Adlercreutz H and Hautanen A. (1996):** Psychosocial stress and the insulin resistance syndrome. *Metabolism*; 45: 1533-1538.
- **Rao G. (2001):** Insulin resistance syndrome. *American Family Physician*; March 15, Volume 63; 6: 1159-1163.
- **Ratziu V, Giral P, Charlotte F, Valentin P, Rony H and Giovani O. (2000):** Liver fibrosis in overweight patients. *Gastroenterology*; 118: 1117-23.
- **Reaven GM. (1988):** Role of insulin resistance in human disease. Banting lecture 1988. *Diabetes*; 37: 1595-607.
- **Reaven GM. (2005):** Second world congress on insulin resistance syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. *Diabetes Care*; 28: 1518-1523.
- **Reynet C and Kahn CR. (1993):** Rad a member of the Ras family overexpressed in muscle of type II diabetic humans. *Science*; 262: 1441-4.
- **Rotter JI. (2005):** Researchers find that variations in four inflammatory genes may predispose Mexican Americans to insulin resistance, a precursor of diabetes. *ADA*; June: 1-3.
- **Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A and Negro F. (2004):** Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut*; 53: 406-412.
- **Russo MW and Jacobson IM. (2002):** Nonalcoholic fatty liver disease. *Hospital physician Novwmbere*; 36: 4-67.

- **Saltiel AR and Olefsky JM. (1996):** Thiazolidinediones in the treatment of insulin resistance and type II diabetes. *Diabetes*; 45: 1661-9.
- **Sanyal AJ, Campbell-Sargent C, Mirshahi F, Reaven G and Ibock T. (2001):** Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology*; 120: 1183-92.
- **Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT and Mills AS. (2003):** Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. *Am J Gastroenterol*; 98: 2064-2071.
- **Sargin H, Sargin M, Gozu H, Orcun A, Baloglu G, Ozisik G, Seker M and Uygur-Bayramidi O. (2005):** Nonalcoholic fatty liver disease and adiponectin. *World J Gastroenterol*; 11(37): 5874-5877.
- **Schwabe RF (2005):** Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. *Hepatology*; 42: 959-961.
- **Sears D and Patel T. (2005):** Fatty liver. *Emedicine*; March: Section 1-9.
- **Sepalla-Lindroos A, Vehkavaara S, Hakinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J and Yki-Jarvinen H. (2002):** Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *J Clin Endocrinol Metab*; 87: 3023-8.
- **Sheth SG, Gordon FD and Chopra S. (1997):** Nonalcoholic steatohepatitis. *Ann Intern Med*; 126: 137-45.
- **Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K and Koike K. (2004):** Hepatitis C virus infection and

- diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology*; 126: 840-848.
- **Shulman GI. (2000):** Cellular mechanisms of insulin resistance. *J Clin Invest*; 106: 171-176.
 - **Silverman EM, Sapala JA and Appelman HD. (1995):** Regression of hepatic steatosis in morbidly obese persons after gastric bypass. *Am J Clin Pathol*; 104: 23-31.
 - **Skurk T, Van Harmelen V, Lee YM, Wirth A and Hauner H. (2002):** Relationship between IL-6, leptin and adiponectin and variables of fibrinolysis in overweight and obese hypertensive patients. *Horm Metab Res*; 34: 659-663.
 - **Sorbi D, McGill DB, Thistle JL, Brown G, Garry N and Dulbin F. (2000):** An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. *Am j Gastroenterol*; 95: 3206-10.
 - **Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H and Pfeiffer AF. (2003):** Adiponectin and protection against type 2 diabetes mellitus. *Lancet*; 361: 226-228.
 - **Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C and Tataranni PA. (2002):** Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosin phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes*; 50: 1884-1888.
 - **Stejskal D, Ruzicka V, Fanfrdlova G, Kolar V and Bartek J. (2005):** High adiponectin and tumor necrosis factor alpha levels in moderate drinkers suffering from liver steatosis: Comparison with non

- drinkers suffering from similar hepatopathy. Biomed Papers; 149(1): 93-99.
- **Struben VM, Hespenheide EE and Caldwell SH. (2000):** Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108: 9-13.
 - **Stumvoll M. (2003):** Thiazolidinediones-some recent developments. Expert Opin Investig Drugs; 12: 1179-1187.
 - **Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH and Dobbins RL. (2005):** Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab; 288: E462-E468.
 - **Targher G, Bertolini L, Scala L, Poli F, Zenari L and Falezza G. (2004):** Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol; (Oxf) 61: 700-703.
 - **Teli MR, James OF, Burt AD, Dan S, Zonder H and Bright W. (1995):** The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology; 22: 1714-9.
 - **Thefeld W, Wallnofer H, Shmidt E and Shmidt FW. (1974):** Dtsch. Med. Wschr; 99: 343.
 - **Tietge UF, Boker KH, Manns MP, and Bahr MJ. (2004):** Hepatic hemodynamics cirrhosis is associated with reduced liver function and altered Elevated circulating adiponectin levels in liver. Am J Physiol Endocrinol Metab; 287: E82-E89.
 - **Trinder P. (1969):** Ann. Clin. Biochem; 6: 24.

- **Trujillo KD, Vizcarra SN, Lopez RO, Marci MN and Tardelli FG. (2005):** Non-alcoholic steatohepatitis related to morbid obesity: Genetic and clinical risk factors. *Gastroenterology*; 128(suppl 2): A-542. [Poster T1745].
- **Umar RK and Rinella ME. (2005):** Nonalcoholic fatty liver disease. Northwestern university, Chicago, Illinois; 94-98.
- **Van Citters GW, Kabir M, Kim SP, Joseph B and Donut T. (2002):** Elevated glucagon-like peptide-1-(7–36)-amide, but not glucose, associated with hyperinsulinemic compensation for fat feeding. *J Clin Endocrinol Metab*; 87: 5191-5198.
- **Vasseur F, Lepretre F, Lacquemant C and Froguel P. (2003):** The genetics of adiponectin. *Curr Diab Rep*; 3: 151-158.
- **Walker KZ, O'Dea K, Johnson L, Recardo H, Carlos M and Robert F. (1996):** Body fat distribution and non-insulin-dependent diabetes: comparison of a fiber-rich, highcarbohydrate, low-fat (23%) diet and a 35% diet high in monounsaturated fat. *Am J Clin Nutr*; 63: 254-260.
- **Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Hakkinen AM, Fredriksson J and Yki-Jarvinen H. (2004):** Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. *Diabetologia*; 47: 1360-1369.
- **Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE and Tataranni PA (2001):** Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab*; 86:1930-1935.

- **Xu A, Wang Y, Keshaw H, Xu LY, Lam KS and Cooper GJ. (2003):** The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *Journal of Clinical Investigation*; 112: 91–100.
- **Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, Okazaki Y, Ishii T, Nishikai K and Saruta T. (2002):** Correlation of the adipocyte derived protein adiponectin with insulin resistance index serum high-density lipoprotein-cholesterol in the Japanese population. *Clin Sci*; 103: 137-142.
- **Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai, R and Kadowaki T. (2003):** Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature*; 423: 762-769.
- **Yamauchi T, Kamon J, Minokoshi Y, Yamamoto T, Takachi H and Subaru T. (2002):** Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nat Med*; 8: 1288-1295.
- **Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Taity and Chuang LM. (2001):** Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. *J Clin Endocrinol Metab*; 86: 3815-3819.
- **Yki-Jarvinen H. (1994):** Pathogenesis of non-insulin-dependent diabetes mellitus. *Lancet*; 343: 91-95.

- **Yoon D, Lee SH, Park HS, Lee JH, Park JS, Cho KH and Kim SM. (2005):** Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. *J Korean Med Sci*; 20: 421-426.
- **Zakrzewska KE, Cusin I, Sainsbury A, Chun G and Burt N. (1997):** Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. *Diabetes*; 46: 717-719.
- **Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M and Reaven GM. (1992):** Prevalence of hyperinsulinaemia in patients with high blood pressure. *J Intern Med*; 231: 235-40.
- **Zhang Y, Matheny M, Zolotukhin S, Tumer N and Scarpace PJ. (2002):** Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of α 3-adrenergic agonists, retinoic acid, leptin and fasting. *Biochim Biophys Acta*; 1584: 115-122.